Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
|
|
- Gabriel Stephens
- 6 years ago
- Views:
Transcription
1 Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis
2 Disclosures AstraZeneca Research Support and Serve on the Executive Committee for the EUCLID trial in symptomatic PAD comparing ticagrelor versus clopidogrel
3 Audience Question 1 In acute coronary syndrome (ACS) patients, a reduction in death vs. clopidogrel was demonstrated with which drug in the PLATO trial? 40% 40% 0% 20% 1. Prasugrel 2. Ticagrelor 3. Aspirin 4. None of these drugs
4 Outcomes Question 2 A 76-year-old male experiences a STEMI, and primary PCI is undertaken with drug-eluting stent implantation. How long would you treat with an oral P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor)? 20% 40% 20% 20% 1. 1 month 2. 6 months months 4. Indefinitely
5 Antiplatelet Agents Desai NR, Bhatt DL. JACC Cardiovasc Intervention. 2010;3:
6 Vascular Death, n Aspirin is Effective in Acute Coronary Syndromes STEMI NSTE-ACS Placebo 568/4300 (13.2%) 500 ASA 461/4295 (10.7%) SK 448/4300 (10.4%) SK + ASA 343/4292 (8.0%) Days After STEMI 35 Lancet 1988;2: Cairns JA et al, NEJM :1369
7 What is the optimal aspirin dose? N=25,086; 2-by-2 factorial design; 30 day follow-up Overall Cohort PCI Cohort Aspirin 325mg Aspirin 81mg P value MACE CV death Major Bleeding Minor Bleeding In the PCI cohort, the endpoint of definite or probable stent thrombosis did not differ between aspirin groups (1.9% vs 2.0%, P=0.36) NEJM 2010;363:930-42; Lancet 2010;376:
8 Cumulative Hazard Rate Dual Antiplatelet Therapy is Effective in the Setting of ACS: CURE Placebo + ASA 20% Relative Risk Reduction Clopidogrel + ASA 0.04 P < N = 12, Months of Follow-Up The CURE Trial Investigators. N Engl J Med. 2001;345:
9 Cumulative Hazard Rate PCI-CURE: Clopidogrel after NSTE-ACS Treated with PCI Composite of MI or cardiovascular death from randomization to end follow-up Placebo + ASA* 12.6% 31% Overall Relative Risk Reduction 8.8% 0.05 Clopidogrel + ASA* P = N = * In addition to other standard therapies Days of follow-up Mehta. et al for the CURE Investigators. Lancet. 2001;358:
10 CURE Trial Major Bleeding by ASA Dose ASA Dose Placebo + ASA Clopidogrel + ASA <100 mg 2.0% 2.6% mg 2.3% 3.5% >300 mg 4.0% 4.9% Yusuf S, et al. N Engl J Med. 2001;345:
11 Death, MI Stroke (%) Dead (%) COMMIT: CLOPIDOGREL in 46,000 AMI Pts Death, Re-MI or Stroke Placebo + ASA: 2311 events (10.1%) Clopidogrel + ASA: 2125 events (9.3%) Placebo + ASA: 1846 deaths (8.1%) Mortality Clopidogrel +ASA: 1728 deaths (7.5%) 9% RRR (P=0.002) 7% RRR (P=0.03) Days since randomisation Days since randomisation Chen et al. Lancet. 2005;366:
12 What is the optimal clopidogrel dose? N=25,086; 2-by-2 factorial design; 30 day follow-up 600mg Load & Double Dose Clopidogrel 300mg Load & Standard Dose Clopidogrel P value MACE CV death Major Bleeding Minor Bleeding NEJM 2010;363:930-42; Lancet 2010;376:
13 Limitations of Clopidogrel Heterogenous antiplatelet response Genetic polymorphisms associated with poor response Drug-drug interaction Smoking interaction Bonello L, JACC 2010;56: Ho PM, JAMA 2009;301: Berger JS, Circulation 2009;120:
14 Impact of Platelet Reactivity after PCI: Meta-Analysis of Individual Patient Data 6 studies 3059 patients Brar et-al. JACC 2011; 58:1945
15 Proportion of Deaths or Recurrent ACS Risk of All-Cause Mortality and Recurrent ACS in Patients Taking Clopidogrel and PPI Neither clopidogrel nor PPI PPI without clopidogrel Clopidogrel + PPI Clopidogrel without PPI Days Since Discharge Ho PM et al. JAMA. 2009;301(9): PPI = Proton Pump Inhibitor
16 COGENT Trial Design Non-STEMI, STEMI, or Elective Stent n=3627 Aspirin Clopidogrel 75 mg and Placebo Clopidogrel 75 mg and Omeprazole (Prilosec) 20 mg Planned enrollment: 5000; stopped due to bankruptcy Mean follow-up 133 days (maximum, 362 days) Bhatt D, et al. NEJM 2010;363:
17 Survival Probability Composite Cardiovascular Events COGENT Trial N=3627 Placebo: 67 events; 1821 at risk Treated: 69 events; 1806 at risk HR= % CI=0.70; Placebo Time (Days) Omeprazole Bhatt D, et al. NEJM 2010;363: Adjusted with Cox Proportional Hazards Model for NSAID use and positive H. pylori status.
18 Probability of Freedom from Primary GI Endpoint COGENT Trial Effect of PPI on Composite GI Events 1.00 Omeprazole Placebo 0.90 HR = 0.34, 95% CI = P < by the log-rank test Time (Days) No. at Risk Placebo Omeprazole Bhatt DL, et al. N Engl J Med. 2010;363(20):
19 CYP2C19 Genetic Polymorphisms and Outcomes With Clopidogrel Major Adverse CV Events (N=9684) Risk Ratio (95% CI) P Value Carriers vs Noncarriers 1.61 ( ) <0.001 Heterozygotes vs Wildtype 1.50 ( ) Homozygotes vs Wildtype 1.81 ( ) Stent Thrombosis (N=5772) Carriers vs Noncarriers 2.76 ( ) <0.001 Heterozygotes vs Wildtype 2.51 ( ) <0.001 Homozygotes vs Wildtype 4.78 ( ) <0.001 Risk Lower With CYP2C19 Variant Relative Risk Risk Higher With CYP2C19 Variant Mega JL, et al. JAMA 2010; 304: Courtesy of JL Mega and MS Sabatine.
20 Clopidogrel Label Changes WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS See full prescribing information for complete boxed warning. Effectiveness of clopidogrel depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1) Poor metabolizers treated with clopidogrel at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (12.5) Tests are available to identify a patient s CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5) Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.1)
21 Metabolism of P2Y 12 Receptor Blockers Schomig A. NEJM 361;11: Ticagrelor and Prasugrel have Rapid Consistent /Greater IPA
22 PRINCIPLE TIMI 44: Comparison with Higher Dose Clopidogrel N=201 IPA (%; 20 mm ADP) P< for each IPA (%; 20 mm ADP) P< Prasugrel 60 mg Clopidogrel 600 mg Hours Wiviott SD et al. Circulation. 2007;116: Clopidogrel 150 mg 14 Days Prasugrel 10 mg 22
23 TRITON-TIMI 38 Study Design ACS (STEMI or UA/NSTEMI) & Planned PCI ASA n=13,600 Double-blind CLOPIDOGREL 300 mg LD/ 75 mg MD PRASUGREL 60 mg LD/ 10 mg MD Median duration of therapy - 12 months 1 o endpoint: CV death, MI, stroke 2 o endpoints: CV death, MI, stroke, rehosp-rec isch CV death, MI, UTVR UTVR = urgent target vessel revascularization; NSTEMI = non-st segment elevation MI Wiviott SD et al. Am Heart J. 2006;152:
24 Endpoint (%) TRITON-TIMI Prasugrel: Efficacy and Safety 10 CV Death / MI / Stroke Clopidogrel HR 0.81 ( ) P= Prasugrel 5 0 TIMI Major NonCABG Bleeds Wiviott, et al, NEJM 2007;357:2001 Days Prasugrel Clopidogrel HR 1.32 ( ) P=
25 Events (%) TRITON-TIMI 38: Bleeding Events 4 Clopidogrel Prasugrel ICH in patients w/ prior stroke/tia (N = 518) Clop 0 (0%) Pras 6 (2.3%) (P = 0.02) 0 TIMI Major Bleeds ARD 0.6% HR = 1.32 P = 0.03 NNT =167 Life Threatening ARD 0.5% HR = 1.52 P = Nonfatal Fatal ICH ARD 0.2% P = 0.23 ARD 0.3% P = ARD 0% P = 0.74 ICH = intracranial hemorrhage; ARD = absolute risk difference; TIA = transient ischemic attack. Wiviott SD et al. N Engl J Med. 2007:357:
26 TRITON-TIMI 38: Summary of the results Mod/high-risk ACS (n=13,608) scheduled for PCI randomized to: Prasugrel (60 mg LD and 10 mg daily MD) or Clopidogrel (300 mg LD and 75 mg daily MD) for 6-15 months Primary end point (CV death, nonfatal MI, nonfatal stroke) 9.9% prasugrel vs 12.1% clopidogrel (HR: 0.81; p<0.001) Prasugrel significant MI (7.4% vs. 9.7%; p<0.001) and stent thrombosis (1.1% vs. 2.4%) Prasugrel significantly increased risk of major bleeding, including fatal bleeding Cardiovascular mortality and overall mortality did not differ significantly between groups Wiviott SD, et al. for TRITON-TIMI 38 Investigators. NEJM 2007;357:
27 TRITON-TIMI 38 Prior Stroke / TIA Yes No Net Clinical Benefit Bleeding Risk Subgroups Post-hoc analysis P int = Risk (%) Age >=75 < 75 P int = Wgt < 60 kg +3 >= 60 kg P int = OVERALL Prasugrel Better Wiviott SD, et al. NEJM 2007;357: HR Clopidogrel Better
28 Black Box Warning with Prasugrel Prasugrel can cause significant, sometimes fatal, bleeding Do not use prasugrel in patients with active pathological bleeding or a history of transient ischemic attack or stroke In patients age 75 and older, prasugrel is generally not recommended because of the increased risk of intracranial and fatal bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior MI). In these situations, the drug's effect appears to be greater, and its use may be considered. Additional risk factors for bleeding include: body weight < 60 kg propensity to bleed concomitant use of medications that increase the risk of bleeding
29 Ticagrelor Cyclopentyl-triazolopyrimidine Rapid oral absorption (30 minutes to onset) No transformation to active metabolite Reversibly binds to P2Y 12 Peak platelet inhibition within hours Half life of 7-8 hours -> twice a day dosing
30 IPA (%; 20 mm ADP, Final) Clopidogrel vs. Ticagrelor ONSET/OFFSET Study Loading Maintenance and Offset * * * Ticagrelor 180mg * * Clopidogrel 600 mg Hours Gurbel PA et al. Circulation. 2009;120: *P<0.0001; P<0.005;, P<0.05, ticagrelor vs clopidogrel.
31 PLATO: Study Design NSTE-ACS (moderate-to-high risk) or STEMI (if primary PCI) Clopidogrel-treated or -naive; randomised within 24 hours of index event (N=18,624) Clopidogrel If pre-treated, no additional loading dose; if naive, standard 300 mg loading dose, then 75 mg qd maintenance; (additional 300 mg allowed pre PCI) Ticagrelor 180 mg loading dose, then 90 mg bid maintenance; (additional 90 mg pre-pci) 6 12-month exposure (median 9 mos) Primary endpoint: CV death + MI + Stroke Primary safety endpint: Total major bleeding Wallentin L, et al. NEJM. 2009;361:
32 Cumulative incidence (%) PLATO: K-M estimate of time to first primary efficacy event (composite of CV death, MI or stroke) Clopidogrel Ticagrelor HR 0.84 (95% CI ), p= No. at risk Days after randomisation Ticagrelor 9,333 8,628 8,460 8,219 6,743 5,161 4,147 Clopidogrel 9,291 8,521 8,362 8,124 6,743 5,096 4,047 K-M = Kaplan-Meier; HR = hazard ratio; CI = confidence interval Wallentin L et al. NEJM.2009;361:
33 % of Events Aspirin with: PLATO: Individual Endpoints Ticagrelor Clopidogrel N = 18,624 Started study drug at median 11.3 hours after chest pain began 12 month follow-up All CV Events MI Stroke CV Death NEJM 2009;361: P<0.001 P=0.005 P=0.22 P=0.001
34 PLATO Bleeding Data Ticagrelor Clopidogrel 14% p= % 10% p=0.57 8% p=0.70 6% 4% p=0.02 2% p=0.66 0% PLATO Major Bleeding TIMI Major Bleeding Life-Threatening or Fatal Bleeding Fatal Bleeding TIMI non-cabg Major Bleeding Wallentin L et al. NEJM 2009;361:
35 PLATO: Summary of the results NSTE-ACS (moderate-to-high risk) STEMI (if primary PCI) (N=18,624) Ticagrelor (180 mg LD and 90 mg bid MD) or Clopidogrel ( mg LD and 75 mg daily MD) for 6-12 months Primary end point (CV death, nonfatal MI, nonfatal stroke), 9.8% ticagrelor vs 11.7% clopidogrel (HR: 0.84; p<0.001) Ticagrelor significant MI (7.4% vs. 9.7%; p<0.001), CV death (4% vs. 5.1%) and stent thrombosis (1.1% vs. 2.4%) Ticagrelor significantly increased risk of non-cabg major bleeding Fatal bleeding was not significantly different between groups Overall mortality was significantly decreased with ticagrelor (4.5% vs. 5.9%; p<0.001) Wallentin L, et al. for PLATO Investigators. NEJM 2009;361:
36 Primary Efficacy Outcome US and ROW by aspirin dose Mahaffey KW et al. Circulation.2011;124:
37 Ticagrelor FDA Label Boxed Warning WARNING: BLEEDING RISK Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal, bleeding (5.1, 6.1). Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage (4.1, 4.2). Do not start ticagrelor in patients planned to undergo urgent coronary bypass graft surgery (CABG). When possible, discontinue ticagrelor at least 5 days prior to any surgery (5.1). Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of ticagrelor (5.1). If possible, manage bleeding without discontinuing ticagrelor. Stopping ticagrelor increases the risk of subsequent cardiovascular events (5.5). WARNING: Aspirin Dose and Ticagrelor Effectiveness Maintenance doses of aspirin above 100 mg reduce the effectiveness of ticagrelor and should be avoided. After any initial dose, use with aspirin mg per day (5.2, 14).
38 How Do Different Antiplatelets Compare in the Setting of ACS? Event CURE TRITON TIMI 38 PLATO Clopidogrel (vs placebo) RR (95% Cl) Prasugrel (vs Clopid) RR (95% Cl) Ticagrelor (vs Clopid) RR (95% Cl) MACE 9.3 vs ( ) MI 5.2 vs ( ) Stroke 1.2 vs ( ) Any Death 5.7 vs ( ) CV Death 5.1 vs ( ) 9.9 vs ( ) 7.3 vs ( ) 1.0 vs ( ) 3.0 vs ( ) 2.1 vs ( ) 9.8 vs ( ) 5.8 vs ( ) 1.5 vs ( ) 4.5 vs ( ) 4.0 vs ( ) Major Bleeding 3.7 vs ( ) 2.5 vs ( ) 11.6 vs ( ) C = Clopidogrel Pl = Placebo Pr = Prasugrel Ti = Ticagrelor
39 What About Medical Therapy in ACS?
40 TRILOGY ACS: Primary Efficacy Endpoint to 30 Months (Age < 75 years) HR (95% CI): 0.91 (0.79, 1.05) P = 0.21 Roe MT et al. N Engl J Med. 2012;367:
41 CV death, MI or stroke (%) PLATO Non-Invasive and Invasive: Primary Outcome Non-invasive HR, 0.85, 95% CI: ( ) 14.3% 12.0% 10.7% 9.0% 5 0 Invasive HR, 0.84, 95% CI: ( ) Number at risk Invasive Days after randomization Ticagrelor Clopidogrel Non-invasive Ticagrelor Clopidogrel James S et al. BMJ 2011;342:d
42 Antiplatelet Rx after ACS I IIa IIb III I IIa IIb III I IIa IIb III After PCI, aspirin should be continued indefinitely. It is reasonable to use 81 mg of aspirin daily in preference to higher maintenance doses (IIa-B). In patients receiving a stent (BMS or DES) during PCI for ACS, P2Y 12 inhibitor therapy should be given for at least 12 months. Options include: - clopidogrel 75 mg daily, - prasugrel 10 mg daily, or - ticagrelor 90 mg twice daily. For UA/NSTEMI patients in whom an initial conservative strategy is selected, clopidogrel or ticagrelor should be administered for up to 12 months ACCF/AHA PCI Guidelines & 2012 ACCF/AHA UA/NSTEMI Focused Update
43 Risk of Any Event Optimizing Antiplatelet Therapy: Balancing Safety and Efficacy High risk of ischemic events Sweet spot High risk of bleeding events Ischemic risk Bleeding risk Risk of Any Event Inhibition of Platelet Aggregation Ferreiro JL, et al. Thromb Haemost. 2010;103:
44 Concept of Platelet Biosignature Treatment Consideration Patient A Patient B Platelet Genetics and/or Platelet phenotype Biosignatures Outcome A or Treatment A Outcome B or Treatment B
45 Thank You
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationP 2 Y 12 Receptor Inhibitors
P 2 Y 12 Receptor Inhibitors Clopidogrel, Prasugrel and Ticagrelor Which Drug and for Whom? Cheol Whan Lee, MD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationRisk of GI Bleeding and Use of PPIs
Risk of GI Bleeding and Use of PPIs ESC 211 August 28, 211 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Associate Professor of Medicine, Harvard
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationand Ticagrelor Professor of Medicine (Cardiology), Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
Role of Genotyping and Point-of-Care of Testing in Clopidogrel, Prasugrel, and Ticagrelor Ron Waksman, MD Ron Waksman, MD Professor of Medicine (Cardiology), Georgetown University Associate Director, Division
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationUpdate on Antiplatelet Therapy
Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationDual Oral Antiplatelet Therapy for ACS: Improving Standards of Care to Optimize Outcomes
Agenda Welcome and Introduction Pathophysiology of ACS Is Aspirin Enough? Overview of Antiplatelet Agents Clopidogrel Prasugrel Ticagrelor New Guideline Recommendations for Dual Antiplatelet Therapy in
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationΚωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο
Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο Europe* 2001 2011 Incident MI 291,100 327,700 US 2001 2011 Incident MI 405,100 485,200
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationTim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
More informationPRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome
CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationCOME ORIENTARSI TRA I NUOVI. Maria Rosa Conte H. Mauriziano Torino
COME ORIENTARSI TRA I NUOVI ANTIPIASTRINIC I Maria Rosa Conte H. Mauriziano Torino Sulle sponde del Ticino- Novara 10 maggio 2013 NEW ORAL ANTIPLATET AGENT PRASUGREL TICAGRELOR (Cangrelor) Death/ MI/
More informationJuly ACCP Cardiology PRN Journal Club 7/23/2018
July ACCP Cardiology PRN Journal Club 7/23/2018 Dr. Michael Plazak Dr. Michael Plazak is a PGY2 Cardiology Pharmacy Resident at the University of Maryland School of Pharmacy. He graduated from the University
More informationUpcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationINNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.
INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies. José G. Díez, MD, FACC, FSCAI Associate Professor of Medicine, Baylor College of Medicine Hall Garcia
More informationOptimal Duration of Dual Anti- Platelet Therapy. December 19, 2015
Optimal Duration of Dual Anti- Platelet Therapy December 19, 2015 John S. MacGregor, M.D., Ph.D. Professor of Medicine University of California San Francisco Source: The New Yorker 1 Optimal Duration of
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationTicagrelor. Platelet Inhibition and Beyond. Christian W. Hamm
Platelet Inhibition and Beyond Christian W. Hamm Medical Clinic I University Hospital Giessen & Kerckhoff Heart and Thorax Center Bad Nauheim, Germany Affiliation/Financial Relationship Conflict of Interest
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationDisclosures. Research consulting with: Sanofi-Regeneron Pfizer The Medicines Company Astra Zeneca
Antiplatelet Therapy in Coronary Artery Disease -2015 What are the roles for newer therapies? How do you decide what to cover? R. Scott Wright, MD, FACC, FESC, FAHA Professor of Medicine, Mayo Clinic College
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More informationSCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationPoint-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time?
Point-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time? Robert G. Wilkins, M.D., F.A.C.C., F.S.V.M New Cardiovascular Horizons May 29, 2015 No Disclosures Dual Anti-Platelet
More informationThe Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationDAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders
DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders Annual Ohio ACC Conference October 14, 2017 Ernest L. Mazzaferri Jr, MD, FACC, FSCAI Disclosures No financial disclosures related to
More informationThe Pharmacogenetics of Clopidogrel
The Pharmacogenetics of Clopidogrel CANNeCTIN Cutting-Edge Pharmacogenetics Symposium May 22, 2009 Marc S. Sabatine, MD, MPH Investigator, TIMI Study Group Associate Physician, Cardiovascular Division,
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationCilostazol: Triple Benefits More is Better!
Cilostazol: Triple Benefits More is Better! Matthew J. Price, MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute,
More informationA patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment
A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment Ronen Durst, MD Cardiology Department Hadassah, Hebrew University Medical Center. Chairman, Israeli society for
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationRobert Storey. Sheffield, United Kingdom
Antiplatelet in ACS Moving beyond clopidogrel Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary Consultant Cardiologist,
More informationAntiplatelet in diabetics: strong but incomplete umbrella
Antiplatelet in diabetics: strong but incomplete umbrella Seung-Whan Lee, MD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Global Projections for the Number
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationSpeaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationA PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI)
A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) Sony Tuteja, PharmD, MS Twitter @sony_tuteja Perelman School of Medicine at the University
More information